Signaturefd LLC Boosts Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Signaturefd LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 10.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,880 shares of the life sciences company’s stock after buying an additional 177 shares during the period. Signaturefd LLC’s holdings in Illumina were worth $251,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ILMN. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in Illumina during the fourth quarter worth approximately $32,000. Assetmark Inc. lifted its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina in the 4th quarter valued at $45,000. Finally, TD Private Client Wealth LLC grew its position in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Performance

NASDAQ:ILMN opened at $87.66 on Friday. The firm’s fifty day simple moving average is $108.20 and its 200-day simple moving average is $128.28. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market cap of $13.89 billion, a PE ratio of -11.41, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Canaccord Genuity Group dropped their price target on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, March 11th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research note on Friday, February 28th. Morgan Stanley lowered their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Finally, Stephens reiterated an “overweight” rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.